Compare OII & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OII | VRDN |
|---|---|---|
| Founded | 1964 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | N/A | N/A |
| Metric | OII | VRDN |
|---|---|---|
| Price | $24.68 | $31.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $25.00 | ★ $39.00 |
| AVG Volume (30 Days) | 744.0K | ★ 1.9M |
| Earning Date | 10-22-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.60 | N/A |
| EPS | ★ 2.29 | N/A |
| Revenue | ★ $2,829,032,000.00 | $70,789,000.00 |
| Revenue This Year | $5.78 | N/A |
| Revenue Next Year | $1.81 | $37,670.06 |
| P/E Ratio | $10.78 | ★ N/A |
| Revenue Growth | 8.71 | ★ 23340.07 |
| 52 Week Low | $15.46 | $9.90 |
| 52 Week High | $30.98 | $32.54 |
| Indicator | OII | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 59.67 | 73.19 |
| Support Level | $22.77 | $28.33 |
| Resistance Level | $24.95 | $32.09 |
| Average True Range (ATR) | 0.74 | 1.08 |
| MACD | 0.14 | 0.13 |
| Stochastic Oscillator | 85.07 | 79.67 |
Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).